Notable Labs Ltd (NTBL) Return on Equity ROE from the second quarter 2024 to second quarter 2023 and annually, average high and low, overall ranking from Jun 30 2024 to Jun 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Notable Labs Ltd   (NASDAQ: NTBL)

Notable Labs Ltd 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Notable Labs Ltd in the second quarter 2024?
Notable Labs Ltd recorded a cumulative net loss of $-24 million during 12 months ending in the second quarter 2024, resulting in a negative return on equity (ROE) of -182.14%.

Within the Major Pharmaceutical Preparations industry 313 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2024 from 2964 to 3621.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter
Y / Y Equity Change - - - -27.53 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -24 -22 -24 -12 -22
Return On Equity (TTM) -182.14 % - - - -
NTBL's Total Ranking # 3621 # 2964 # 0 # 33 # 0
Equity (TTM) in Millions 7 12 15 18 -46
Seq. Equity Change -37.76 % -23.61 % -17.58 % - -
Seq. Net Income Change - - - - -

Back to NTBL Management Effectiveness >> NTBL's 5 Years Annual ROE >> Compare NTBL ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 314
Sector # 694
Overall # 3621

Return On Equity Statistics
High Average Low
234.43 %
28.9 %
-182.14 %
(Jun 30 2023)   (Jun 30 2024)



  News about Notable Labs Ltd Return on Equity ROE

Notable Labs Announces CEO Transition amid Challenging Financial Performance



In a recent announcement, Notable Labs Ltd, a pioneering biotech company focused on personalized cancer therapy, disclosed a change in its leadership as Thomas Bock, MD, stepped down as CEO. Joseph Wagner, PhD, the company s Chief Scientific Officer (CSO), has been appointed as the interim CEO. This change comes at a crucial time for Notable Labs as it has reported a significant net loss and negative return on equity (ROE) for the first quarter of 2024.
Challenging Financial Performance:
During the twelve months leading up to the first quarter of 2024, Notable Labs Ltd recorded a cumulative net loss of $-18 million, reflecting a substantial decline in its financial position. The negative net loss has resulted in a concerning negative return on equity (ROE) of -110.03%, signaling the company s struggle to generate profits for its shareholders. These financial results have undoubtedly contributed to the need for a CEO transition and the subsequent appointment of Joseph Wagner as the interim CEO.



NTBL Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions 15 -37 -54 31 36
Y / Y Equity Change - - - -14.17 % -32.24 %
Net Income in Millions -11 32 30 24 0
Y / Y Net Income Change - 7.97 % 23.51 % - -
Return On Equity -74.53 % - - 78.35 % 0 %

Back to NTBL Management Effectiveness >> NTBL's 5 Years Annual ROE >> Compare NTBL ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NTBL's' Return on Equity at Yahoo Finance
NTBL's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NTBL's Competitors
Subscribers only: Roe for Notable Labs Ltd 's Suppliers
Subscribers only: Return On Equity for NTBL's Customers




Companies with similar Return On Equity at Jun 30 2024, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.